Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses (2016 - 2025)

Historic Interest Expenses for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to $6798.0.

  • China Pharma Holdings' Interest Expenses fell 65.76% to $6798.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $27166.0, marking a year-over-year increase of 11169.81%. This contributed to the annual value of $27353.0 for FY2024, which is 1052.92% down from last year.
  • Latest data reveals that China Pharma Holdings reported Interest Expenses of $6798.0 as of Q3 2025, which was down 65.76% from $6779.0 recorded in Q2 2025.
  • China Pharma Holdings' Interest Expenses' 5-year high stood at $333441.0 during Q4 2021, with a 5-year trough of -$252776.0 in Q4 2023.
  • Its 5-year average for Interest Expenses is $55521.5, with a median of $66240.0 in 2023.
  • Its Interest Expenses has fluctuated over the past 5 years, first soared by 20889.9% in 2021, then tumbled by 36282.92% in 2023.
  • Quarter analysis of 5 years shows China Pharma Holdings' Interest Expenses stood at $333441.0 in 2021, then plummeted by 71.16% to $96175.0 in 2022, then plummeted by 362.83% to -$252776.0 in 2023, then soared by 102.69% to $6802.0 in 2024, then fell by 0.06% to $6798.0 in 2025.
  • Its Interest Expenses stands at $6798.0 for Q3 2025, versus $6779.0 for Q2 2025 and $6787.0 for Q1 2025.